[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"fan li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100571306","phase-2-neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer-100571306",false,"NCT06718543","Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","A Multicenter, Randomized, Parallel, Non-Controlled, Prospective Phase II Study of Neoadjuvant Short-Course Radiotherapy Sequential With AK112 With or Without Chemotherapy for Locally Advanced Rectal Cancer","TRIUNITE-03","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Age 18-80 years, male or female.\n3. Histologically confirmed rectal adenocarcinoma.\n4. Clinical baseline stage T3-4NxM0 or TxN1-2M0 by MRI assessment.\n5. Able to swallow tablets.\n6. ECOG Performance Status of 0-1.\n7. No prior treatment for rectal cancer, including surgery, radiotherapy, 8.chemotherapy, immunotherapy, or targeted therapy.\n\n9.Fit for surgery with no contraindications. 10.Normal organ function. 11.Tumor ≤12 cm from the anal verge\n\nExclusion Criteria:\n\n1. Allergy to monoclonal antibodies, AK112 components, or CapeOX regimen.\n2. Previous or current use of immune checkpoint inhibitors or immune-related 3.treatments.\n\n4.Active autoimmune diseases or history of significant autoimmune conditions. 5.Immunodeficiency disorders or history of organ\u002Fbone marrow transplantation. 6.Uncontrolled cardiovascular conditions (e.g., heart failure, unstable angina, recent MI).\n\n7.Severe infection within 4 weeks or active pulmonary infections. 8.Active hepatitis B or C infection. 9.Diagnosis of other malignancies within 5 years (except low-risk cancers). 10.Pregnant or breastfeeding women.","ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally advanced rectal cancer (LARC). The study also aims to identify biomarkers predicting tumor response and develop efficacy prediction models.",[28],"Rectal Cancer",[30,31,32,33],"rectal cancer","neoadjuvant","Ivonescimab","Immunotherapy","RECRUITING","2025-04-08",{"date":37,"type":38},"2025-04-10","ACTUAL",{"date":40,"type":38},"2025-02-10",{"date":42,"type":22},"2027-10-31",{"name":44,"class":45},"fan li","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100533422","no-stoma-vs-ghost-stoma-in-patients-undergoing-total-mesorectal-excision-for-rectal-cancer-100533422","NCT06225609","No Stoma VS Ghost Stoma in Patients Undergoing Total Mesorectal Excision for Rectal Cancer","Ghost Ileostomy Group Versus no Stoma Group in Patients Undergoing Total Mesorectal Excision for Rectal Cancer: A Randomized Controlled Study","Inclusion Criteria:\n\n* Pathologically confirmed rectal cancer.\n* age ≥18 years and ≤80 years.\n* intraoperative ghost ileostomy or no stoma was performed.\n\nExclusion Criteria:\n\n* ASA score \\>3.\n* Patients with coexisting complete intestinal obstruction.\n* History of long-term use of immunosuppressive drugs or glucocorticoids.\n* Combined severe cardiac disease: with congestive heart failure or NYHA cardiac function ≥ grade 2.\n* Patients with a history of myocardial infarction or coronary artery surgery within 6 months before the procedure.\n* chronic renal failure (requiring dialysis or glomerular filtration rate \\\u003C30 mL\u002Fmin).\n\nIntraoperative combined multi-organ resection.\n\n* Combined cirrhosis of the liver.\n* Intraoperative findings of incomplete anastomosis and positive insufflation test.",true,{"count":56,"type":22},500,[58],"NA","This study aimed at comparing the Comprehensive Complication Index (CCI), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with ghost ileostomy group versus no ileostomy group after total mesorectal excision for rectal cancer.",[61],"Rectal Neoplasms",[63,64,65],"Ghost ileostomy","No ileostomy","Rectal cancer","NOT_YET_RECRUITING","2024-01-17",{"date":69,"type":38},"2024-01-26",{"date":71,"type":22},"2024-03-01",{"date":73,"type":22},"2027-03-01",{"name":44,"class":45},""]